Clinical Trial: Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Metastatic Castration-resistant Prostate Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase II Study of Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
Brief Summary:
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion.The main question[s] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants.Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles.Each cycle is about 21 days.
Read more